Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
on-demand webinar

Immunotherapy advancements: transforming cancer treatment

In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.

This webinar will offer a comprehensive exploration of the current landscape of immunotherapy research. Our esteemed panel will provide detailed insights into recent developments, including both successes and obstacles encountered within the field. We will examine the evolving methodologies and emerging technologies shaping immunotherapy, while also considering the challenges that researchers face. Additionally, we will discuss potential future directions for the field, highlighting opportunities for further advancement.

Our panellists will highlight the expanding spectrum of indications for immunotherapy and its potential in diverse cancer scenarios. Additionally, we’ll tackle the significant challenge of overcoming resistance to immunotherapy, discussing strategies like combination therapies, biomarker-guided approaches, and innovative treatment methods.

Furthermore, our panellists will discuss the concept of tailored immunotherapy, which aims to customise treatment strategies based on individual patient characteristics including tumour genetics and immune profiles, and its implications for patient care.

Key learning points:

– Expanding indications: immunotherapy has demonstrated remarkable efficacy across various cancer types, including melanoma, lung cancer, and haematological malignancies. We’ll discuss the expanding indications for immunotherapy and its potential applications in diverse cancer settings.
– Overcoming resistance: despite its successes, resistance to immunotherapy remains a significant challenge. We’ll explore strategies to overcome resistance mechanisms, including combination therapies, biomarker-driven approaches, and novel treatment modalities.
– Precision immunotherapy: personalised or precision immunotherapy aims to tailor treatment approaches based on individual patient characteristics, including tumour genetics and immune profiles. We’ll explore into the latest advancements in precision immunotherapy and its implications for patient care.
– Future directions and challenges: looking ahead, we’ll discuss emerging trends, ongoing pre-clinical research, and the evolving landscape of immunotherapy research. Additionally, we’ll address key challenges such as immune-related toxicities, biomarker identification, and access to innovative therapies.

Join us as we navigate through the latest advancements in immunotherapy research in a balanced and informative discussion.

Register to join this webinar for free

OUR SPEAKER

 
Speaker

Dr Nicholas Siciliano, PhD, CEO and Co-Founder of Vittoria Biotherapeutics

Dr Nicholas Siciliano has over 15 years of experience in Senior Leadership positions at biotechnology companies and over 20 years of experience as a scientist, inventor, and entrepreneur. He also serves as an Entrepreneur in Residence at Agent Capital and as an investment advisor for both Tellus BioVentures and Valley Forge Investment Corporation.

 
Speaker headshot

Zhimei Du, PhD., Chief Scientific Officer of BlueSphere Bio

Zhimei Du, PhD, is a leader in the fields of cell and gene therapy and biologics, bringing more than 20 years of experience in both early and late-stage therapeutic development. As Chief Scientific Officer of BlueSphere Bio, Dr Du leads the R&D organisation, directing efforts toward the further advancement of TCR-based therapeutic development across various disease areas.

Prior to joining BlueSphere Bio, Dr Du served as Vice President at Atara Biotherapeutics, where she focused on accelerating the progress of both early and late-stage cell therapy pipelines, and later as Vice President at Landmark Bio, where she built and oversaw Translational Research and Early Development. Notably, her tenure at Merck & Co. as Executive Director and Global Head of Process Cell Sciences saw her establish innovative core functions and multi-site teams on a global scale, particularly in cell therapy and biologics development. In addition, Dr Du has been instrumental in driving successful business development initiatives by evaluating and forging partnerships in biologics, ADC, cancer vaccine, CAR-T, and CAR-NK programs. Her extensive research contributions encompass a myriad of patents and publications in cell and gene therapy, process development, protein engineering, cell engineering, vector engineering, and genetic/epigenetic biomarker development.

Dr Du’s academic journey commenced with an MD from Beijing University Medical School, followed by a PhD in Immunology from Cornell University Medical College. She further honed her expertise as a Postdoctoral Fellow in the laboratory of Robert G. Roeder at The Rockefeller University, renowned for its groundbreaking contributions to transcription, in vitro transcription, and epigenetics.

 

Philipp Spycher, PhD, Co-Founder & Chief Scientific Officer of Araris Biotech

As the inventor of the Araris ADC Technology, Philipp has a profound background in Bioconjugation and ADCs. He was the founding CEO since the inception of Araris in 2019 securing $40M in financing from Swiss, UK, US and Korean investors and $2.5M non-dilutive financing from the Swiss Accelerator Grant (5% funding rate). He positioned Araris to shift the paradigm in how to think about developing targeted cancer therapies and since October 2023, he transitioned to become its CSO. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris ADC Technology. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering.

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 29th July at 15:00 BST

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.